Overview

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993

Status:
COMPLETED
Trial end date:
2024-09-10
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-993 in healthy adult participants.
Phase:
PHASE1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated